Results: Fifty-nine randomized and 8 nonrandomized trials addressed 8 interventions: acaricide, air purification, carpet removal, high-efficiency particulate air filtration (HEPA) vacuums, mattress covers, mold removal, pest control, and pet removal. Thirty-seven studies evaluated single-component interventions, and 30 studies assessed multicomponent interventions. Heterogeneity precluded meta-analysis. For most interventions and outcomes, the evidence base was inconclusive or showed no effect. No interventions were associated with improvement in validated asthma control measures or pulmonary physiology. Exacerbations were diminished in multicomponent studies that included HEPA vacuums or pest control (moderate strength of evidence [SOE] for both). Quality of life improved in studies of air purifiers (SOE: low) and in multicomponent studies that included HEPA vacuums (SOE: moderate) or pest control (SOE: low). Conclusions: Single interventions were generally not associated with improvement in asthma measures, with most strategies showing inconclusive results or no effect. Multicomponent interventions improved various outcomes, but no combination of specific interventions appears to be more effective. The evidence was often inconclusive because of a lack of studies. Further research is needed comparing the effect of indoor allergen reduction interventions on validated asthma measures, with sufficient population sizes to detect clinically meaningful differences. (J Allergy Clin Immunol 2018;141:1854-69.)
Key words: Asthma, allergens, environmental, house dust mites, carpet, pests, pets, air purification, high-efficiency particulate air filtration vacuums, mattress covers Control of common environmental factors that contribute to asthma is an important component of asthma management. Many indoor inhalant allergens are associated with increased risk of asthma symptoms and exacerbations, including animal dander, cockroaches, house dust mites, mice, and mold. 1 Numerous interventions have been designed to reduce exposure to these allergens, including use of acaricides (dust mite pesticides), air-purification systems, carpet removal, high-efficiency particulate air filtration (HEPA) vacuums, allergen-impermeable mattress covers, mold removal, pest-elimination techniques, and removal of family pets.
In 1991, the National Asthma Education and Prevention Program (NAEPP), a project of the National Heart, Lung, and Blood Institute (NHLBI), produced clinical practice guidelines addressing the diagnosis, evaluation, and treatment of asthma, including reducing exposure to indoor inhalant allergens. The guidelines were updated subsequently, most recently in 2007. 2 In 2016, the NHLBI convened a working group to oversee a new update of the guidelines. After receiving input from the public, NAEPP Coordinating Committee Members and affiliates, and members of the 2007 Expert Panel, the working group identified 6 high-priority topics for updating. For each topic, key questions were developed to guide new systematic literature reviews. The NHLBI engaged the Agency for Healthcare Research and Quality (AHRQ) to perform the systematic reviews through its Evidence-based Practice Centers (EPCs). In this article we summarize the resulting systematic review on ''Effectiveness of indoor allergen reduction in management of asthma.'' The complete review is available at https:// effectivehealthcare.ahrq.gov/topics/asthma-nonpharmacologictreatment/final-report-indoor-allergen-reduction.
METHODS
We searched Embase, MEDLINE, PubMed, CINAHL, and the Cochrane Library up to April 21, 2017 . We also browsed the Web sites of relevant agencies and organizations to identify ''gray literature,'' such as reports, white papers, dissertations, or other documents not published in peer-reviewed sources. Two independent reviewers performed abstract and full-text screening, with disagreements resolved by means of consensus.
We included only full-length peer-reviewed studies. Systematic reviews, meta-analyses, randomized controlled trials (RCTs), and nonrandomized interventional studies with concurrent controls (eg, nonrandomized trials) or historical controls (eg, pre-post studies) were eligible for inclusion. In vivo, in vitro, and animal studies were excluded. Studies published in a foreign language with English-language abstracts were considered for inclusion if they examined interventions or reported outcomes not sufficiently addressed in English-language studies or provided novel data that might affect our conclusions. Studies were excluded if more than 15% of participants were not given a diagnosis of asthma or if outcomes for asthmatic patients were not reported separately from patients without asthma.
In accordance with the approach used by the ''Guidelines for the diagnosis and management of asthma,'' 2 we defined ''pediatric'' or ''child'' populations as including patients aged 11 years or less and ''adult'' populations as including patients aged 12 years or older. Studies that included patients in both categories are described as having a ''mixed population.'' We limited our review to studies that examined a single intervention or a set of interventions designed to decrease exposure to 1 or more of the following sources of indoor allergens: dust mites, household pets, rodents, cockroaches, or mold. Interventions addressing other indoor allergens or irritants, such as tobacco smoke, indoor pollution, and endotoxin, were excluded. We examined the following interventions selected to reflect the input of the NHLBI Advisory Council Asthma Expert Working Group 3 : acaricides, air-purification devices, carpet or rug removal, HEPA vacuums, impermeable mattress covers, mold removal, pest control, and pet removal.
Data elements abstracted included general study characteristics, patient characteristics, details of interventions, outcomes data, and risk of bias for each study. Risk of bias was assessed by 2 independent reviewers using the Cochrane Collaboration's tool for RCTs 4 and the Newcastle-Ottawa scale 5 for nonrandomized studies. Because of the heterogeneity of the included studies, we did not attempt to combine data from the studies quantitatively.
Outcomes were selected to be consistent with the recommendations of the 2010 Asthma Outcomes Workshop. 6 Primary outcomes included validated measures of asthma control (eg, the Asthma Control Questionnaire 7 or Asthma Control Test [ACT] 8 ), asthma-related exacerbations, asthma-related health care use and costs, pulmonary physiology (eg, spirometric measures), and asthma-related quality of life (eg, the Asthma Quality of Life Questionnaire [AQLQ]). 9 Nonvalidated measures of asthma symptoms and allergen levels were assessed as secondary outcomes.
We graded the strength of evidence (SOE) for each outcome based on guidance established by the EPC program. 10 This approach incorporates 5 key domains: study limitations, consistency, directness, precision, and reporting bias. Overall SOE was evaluated as high, moderate, low, or insufficient. Evidence based on RCTs was assigned an initial SOE of ''high,'' whereas evidence based on non-RCTs was assigned an initial SOE of ''low.'' The SOE was then downgraded as appropriate based on the 5 domains.
We determined study limitations by appraising the degree to which the included studies for the given comparison and outcome had adequate protection against bias (ie, had good internal validity). In general, we downgraded for study limitations when 50% or more of the studies evaluated for a given outcome were at ''high'' overall risk of bias, as described above. When 50% or more of the studies were at ''medium,'' ''low,'' or ''unclear'' risk of bias, we did not downgrade for study limitations.
We assessed consistency of results in terms of the direction and magnitude of effect. In general, we downgraded for inconsistency when there was heterogeneity in the effects of an intervention across studies for a given outcome that could not be explained through identifiable differences in study characteristics. We downgraded for unknown consistency when only a single study was included for an outcome.
The evidence was considered indirect if the populations, interventions, comparisons, or outcomes used within studies did not directly correspond to the comparisons we were evaluating.
Precision is the degree of certainty surrounding an effect estimate with respect to a given outcome and might be affected by sample size, number of events, and width of CIs. In some cases we downgraded the SOE by 2 levels because of substantial imprecision resulting from very small samples or numbers of events or when it was not possible to assess an estimate of effect based on available data (eg, measures of variance were not included or results were presented graphically without reporting of specific data points).
Reporting bias includes publication bias, outcome-reporting bias, and analysis-reporting bias. Given the small number of studies we evaluated for most of the interventions, we did not examine funnel plots. We downgraded for reporting bias when we detected a likelihood of outcome reporting bias (important clinical outcomes appear to have been collected but not reported by the studies within a comparison) or analysis reporting bias (important comparisons were not analyzed). For studies that had commercial funding, authorship, or both, we also assessed the size and direction of any effect compared with the studies that did not receive commercial support to identify possible publication or reporting bias.
We also conducted a qualitative comparative analysis 11 to evaluate the studies. This analytic technique was incorporated to determine whether specific individual strategies or bundles of allergen reduction interventions might be more likely to improve asthma outcomes.
A complete description of the methods used in this review are included in the EPC report. 
RESULTS
We reviewed 1921 abstracts and 201 full-text studies. We included 59 RCTs (with data published in 63 published articles) and 8 nonrandomized controlled studies in the review (Fig 1) . Thirty-seven studies evaluated single interventions, and 30 studies examined multicomponent strategies. Use of mattress covers was the most frequently examined intervention and was included in 33 studies. Conversely, pet removal was implemented in just 3 studies. Twenty-two studies included only patients 12 years of age and older, whereas 9 studies were limited to children less than 12 years of age. Thirty-five studies enrolled patients greater than and less than age 12 years, and 1 study did not report age. Thirty-four studies were conducted in Europe, 23 were performed in the United States, and the remaining 10 were conducted in Canada, Australia, New Zealand, or Asian countries. In 40 studies all patients were sensitized to a relevant allergen, and an additional 14 studies reported that a majority of patients were sensitized. Sensitization was confirmed through skin prick tests in 43 RCTs and with blood tests in the remaining 11 trials. Table I 12-78 provides an overview of the distribution of the studies. Table II 49-78 shows the combinations of interventions used in multicomponent studies. Table III 12-42,46-49,64 summarizes the SOE for each intervention.
A more detailed description of the analysis is presented in Tables IV (for single-intervention studies) and V (for multicomponent studies). [49] [50] [51] [52] [53] [54] [55] [56] [57] [58] [59] [60] [61] [62] [64] [65] [66] [67] [68] [69] [70] [71] [72] 74, 75, 77 Additional information for each included study is available in the complete AHRQ report (https:// effectivehealthcare.ahrq.gov/topics/asthma-nonpharmacologictreatment/final-report-indoor-allergen-reduction).
Acaricides
Seven studies examined use of acaricides on mattresses, carpets, and upholstery as a single intervention to eradicate house dust mite allergens. [12] [13] [14] [15] [16] [17] [18] There was no improvement in pulmonary physiology when comparing acaricides with placebo (moderate SOE) or with other interventions (SOE: low), and other outcomes were inconclusive or not reported. Six multicomponent studies also examined acaricides 51, 65, [67] [68] [69] [70] and suggested no improvement in pulmonary physiology (SOE: moderate) or asthma symptoms (SOE: high). Acaricides reduced dust mite allergen burden (SOE: low), but other outcomes were inconclusive or not reported.
Air purification
Nine studies evaluated air purification as a single intervention. [19] [20] [21] [22] [23] [24] [25] [26] [27] The evidence for asthma control was inconclusive, and no difference was observed for exacerbations or pulmonary physiology measures (SOE: low). For quality of life, 1 study found that AQLQ scores improved (SOE: low), whereas 2 studies that used nonvalidated quality of life measures found no effect (SOE: low). Five studies evaluated air purifiers within multicomponent interventions 49, 50, 59, 61, 78 and reported no improvement in asthma control (SOE: low), exacerbations (SOE: high), or quality of life (SOE: high). However, school absenteeism decreased (SOE: low), asthma symptoms improved (SOE: low), and allergen levels were reduced (SOE: moderate).
Carpet removal
No studies looked solely at removal of carpeting; however, 8 multicomponent studies encouraged patients to remove carpet from their homes, but it is unclear how widely this recommendation was implemented. 51, 52, 54, 58, 68, 71, 72, 77 Allergen levels were reduced in these studies (SOE: moderate), but the evidence is inconclusive for the other outcomes. CHW, Community health worker. *Implemented by some, but not all, study participants. Not an RCT.
HEPA vacuum
One study examined HEPA vacuums alone, but the evidence base is insufficient to support conclusions. 28 Eight multicomponent studies also evaluated HEPA vacuums. 50, 53, 55, 60, 61, 64, 75, 77 The evidence was insufficient for asthma control and pulmonary physiology measures. Exacerbations were reduced (SOE: moderate), medication use did not change (SOE: high), and no effect was observed for school (SOE: low) or work (SOE: moderate) absenteeism. Quality of life improved in studies of children less than 12 years old (SOE: moderate). In addition, asthma symptoms improved in children (SOE: low) but not among mixed populations of children, adolescents, and adults (SOE: moderate).
Mattress covers
Fourteen studies examined impermeable mattress covers, [29] [30] [31] [32] [33] [34] [35] [36] [37] [38] [39] [40] [41] [42] and 3 studies evaluated other approaches designed to limit dust mite allergens on bedding. [43] [44] [45] The evidence suggests no difference in asthma control (SOE: moderate), exacerbations (SOE: moderate), inhaled corticosteroid use (SOE: low), rescue medication use (SOE: high), pulmonary physiology (SOE: high), quality of life (SOE: high), or self-reported asthma symptoms (SOE: high). Conversely, these studies reported reductions in dust mite allergen levels (SOE: moderate). Mattress covers were also used in 19 multicomponent intervention studies. [49] [50] [51] [52] 54, 55, 58, 59, 61, 62, [65] [66] [67] [68] [69] [70] [71] 74, 76 In these studies no improvement was found for emergency department use (SOE: low), hospitalizations (SOE: high), or acute care visits (SOE: moderate). However, school absenteeism and missed activities decreased (SOE: low). No effect was observed for measures of pulmonary physiology (SOE: high) or quality of life (SOE: moderate).
Mold removal
There were no single-intervention studies examining mold removal. Six multicomponent studies examined mold removal [56] [57] [58] [76] [77] [78] and found that asthma symptoms improved (SOE: low), but findings for other outcomes were inconclusive.
Pest control
One RCT 46 and 1 nonrandomized study 47 examined pest-control strategies alone and the findings were insufficient to support any conclusions other than improvement in selfreported asthma symptoms (SOE: low). Thirteen multicomponent studies evaluated pest-control efforts. 49, 52, 54, 55, [58] [59] [60] [61] [62] 66, [74] [75] [76] The evidence was inconclusive for asthma control, medication use, and pulmonary physiology measures. Exacerbations were reduced when measured as a composite score (SOE: moderate), but no effect was observed for discrete measures, including emergency department visits (SOE: moderate) and hospitalizations (SOE: high). School absenteeism decreased (SOE: low) and quality of life among children (SOE: low) improved. Asthma symptoms also improved (SOE: low), and allergen levels were reduced for some pests (eg, cockroaches; SOE: low). 
Pet removal
One nonrandomized study focused on pet removal. 48 The evidence for hospitalizations, medication use, and follow-up visits was inconclusive, and no other asthma outcomes were reported. Two multicomponent interventions encouraged pet removal, 51 ,58 but we did not evaluate the SOE because of the small number of studies and uncertainty regarding how widely this recommendation was implemented.
Qualitative comparative analysis
We included 30 multicomponent and 19 individual intervention studies in the qualitative comparative analysis. The results were not robust, and no intervention or bundle of interventions was necessary or sufficient for improvement in any primary outcome. Overall, the analysis reinforced the findings described in our SOE assessment: there is insufficient evidence demonstrating the effects of most single interventions or multicomponent strategies on important asthma outcomes.
DISCUSSION
This systematic review identified 59 RCTs and 8 non-RCTs addressing 8 interventions for reducing home-based indoor allergen exposure and improving asthma outcomes. Thirty-seven studies evaluated single-component interventions, and 30 studies assessed multicomponent interventions. Overall, we found no high-strength evidence suggesting improvement in any of the primary outcomes, but there was low-to moderatestrength evidence for some interventions. Validated measures of asthma control were reported infrequently. Our findings are generally consistent with previous Cochrane reviews of similar interventions but differ from some other reviews. For example, in a Cochrane systematic review addressing mattress covers and acaricides 79 and another that examined air-purification devices, 80 evidence was generally lacking in rigor and insufficient to inform conclusions. Conversely, a 2010 systematic review 81 found evidence supporting pest control, mold removal, and multicomponent interventions that are individually tailored to a patient or family. However, the authors did not use a formal approach for assessing the strength of the evidence base, and they incorporated expert opinion and epidemiologic evidence drawn from noninterventional studies into their conclusions. Also, they emphasized evidence showing reduced allergen levels on mattresses and floors when clinical outcomes were lacking.
Similarly, our assessment varies in key ways from the 2007 NAEPP guidelines 2 and clinical practice parameters of the American Academy of Allergy, Asthma & Immunology. 82 We found that the evidence for most interventions was low strength or insufficient, whereas the previous guidelines found greater evidence of benefit associated with some interventions.
Several reasons can account for our different conclusions. Our review includes numerous studies published recently, some of which showed no intervention effect. Additionally, we did not always select the same studies as other reviewers because of differences in our respective inclusion criteria. We also prioritized outcomes and examined specific outcome measures differently from the American Academy of Allergy, Asthma & Immunology and the 2007 NAEPP, which affected how our findings were synthesized. Furthermore, our report used different instruments to assess the risk of bias of individual studies, which in turn affected our analysis of the SOE. Finally, the prior reviews did not use the EPC methodology 10 or a similar Grading of Recommendations Assessment, Development and Evaluation (GRADE) 83 type of approach to evaluate the evidence base. These differences might account for variations between our assessment and the preceding reviews.
We found a high level of heterogeneity across studies, particularly related to patient characteristics and combinations of treatments examined, and this limited our ability to assess generalizability to the overall population of patients with asthma. First, variability in patients' baseline clinical characteristics suggests that patients were not equally likely to benefit from the interventions. Although 40 RCTs reported that all patients were sensitized to an allergen and 14 more trials confirmed sensitization in a majority of patients, only 43 studies used skin prick tests to confirm sensitization, whereas 13 studies measured sensitization by using blood tests (a less reliable predictor of true allergy). Therefore some patients in these studies might have been unlikely to benefit from the interventions if they were not allergic. This might affect the results of our analysis.
A similar consideration is variation in asthma severity. Only 18 RCTs classified the severity of participants' asthma. In 11 studies, most or all patients had moderate-to-severe asthma, whereas most patients had mild-to-moderate asthma in 5 studies. In 2 studies the populations were distributed evenly among patients with mild, moderate, and severe asthma. Unfortunately, because 41 RCTs did not report severity, it is difficult to determine how disease severity might have affected our results and whether these studies are representative of the broader population of patients with asthma.
We also note that home-based interventions are difficult to implement properly and completely because cost, language, technology, home ownership, and health literacy can be barriers. Thirteen of the 30 multicomponent intervention studies included a community health worker who received specialized training to educate patients about reducing home allergen exposure in a highly tailored way. Although we did not evaluate the direct effect of these health workers, their role in the process might be important. Similarly, it is difficult to evaluate or ensure fidelity to a home-based intervention. Although several studies reported that adherence to study protocols was evaluated periodically (through surveys or home visits), most studies did not report such findings. Conversely, it is possible and even likely that some control group households adopted allergen-reducing interventions during their studies, potentially masking or minimizing differences in outcomes between study groups. The studies we evaluated did not address or adjust for this type of confounding.
It might also be difficult to maintain an allergen reduction strategy over time. Many studies had high attrition rates, which are attributable partly to participants moving from one home to another or encountering instability in family life that can disrupt continuity. Additionally, some of the interventions might have evolved over time. For example, contemporary air-purification devices might be different from those technologies available and examined 2 or 3 decades earlier, and this could introduce further heterogeneity into the results.
Another important factor is the potential exposure to indoor allergens outside the home. Asthmatic patients are exposed frequently to allergens at work or school or while engaged in other activities, which might limit the effectiveness of interventions used solely at home. Although our review was designed to include studies that evaluated interventions in work or school environments, we did not identify any eligible studies that fit those criteria.
We also note that standardized measures of asthma control, exacerbations, health care use, and quality of life were reported infrequently. Few studies included discrete and validated outcome measures that have established thresholds for clinical significance, such as the ACT or AQLQ. Furthermore, composite outcome measures were used frequently, but their components were not uniform. The relative paucity of studies using validated and standardized measures limited our interpretation of the results.
Overall, the most important limitation of the evidence base we reviewed is the lack of conclusive, consistent, high-or moderatestrength evidence that either favors or does not favor these interventions. We found inconclusive evidence for many comparisons and outcomes and low-strength evidence or no effect for many others. We must emphasize in this context the critical distinction between a lack of evidence and evidence of no effect. Throughout this review, we found that the evidence base lacks sufficient high-quality studies to inform useful conclusions for these interventions. This does not indicate that the interventions are ineffective but rather highlights the need for additional research.
We identified several evidence gaps that would benefit from future research. First, there has been insufficient evaluation of several specific interventions, including HEPA vacuums, carpet removal, pet cleaning or removal, and mold removal. Head-tohead studies of interventions are also missing from the current evidence base, which consists almost entirely of comparisons with placebos or standard practices. Research is also needed to evaluate multicomponent interventions more efficiently. This might be accomplished by standardizing sets of strategies that could be tested as bundles. Additionally, future research could attempt to directly compare single interventions with bundled interventions.
We also need research to establish thresholds for clinically significant change in many of the asthma outcomes examined. Thresholds exist for some outcome measures, such as the ACT and AQLQ, but there are no agreed upon standards for the outcomes that were most frequently improved in the studies we reviewed, including measures of exacerbations, absenteeism, peak flow, asthma symptoms, and allergen reduction.
We also highlight the need for studies that recognize the complex set of challenges facing low-income and minority groups. Although these patients are at higher risk of allergen exposure and significant morbidity, most of the studies we reviewed did not describe the socioeconomic context of their patient population, and only 14 RCTs (24%) seem to have included a substantial number of patients living in poverty, inner-city settings, or both. Finally, assessment of differences in outcomes by age (ie, children versus adults) needs exploration. For example, younger patients are most likely to be truly allergic and have exacerbations related to allergen exposure, but these differences are not adequately addressed in the current literature.
This review highlights an important consideration for clinicians. Because asthma significantly affects overall health and quality of life, patients and their families are often motivated to augment medical treatment with interventions that reduce exposure to allergen triggers. It is important for clinicians to consider the complexity of their patient population and the limitations of the evidence we have identified. When recommending specific steps of action, clinicians might find it helpful to consider a patient's individual sensitization and reaction to specific allergens, as well as the severity of the patient's asthma and the extent of previous symptoms and exacerbations. Meanwhile, further research on the effectiveness of common allergen-control strategies and the many patient-and household-level characteristics that might influence patient outcomes is necessary.
Despite an extensive evidence base spanning several decades, the evidence base as a whole is insufficient to support meaningful conclusions about the effectiveness of many widely used products and strategies for improving patient outcomes by reducing environmental allergen exposure. For many important outcomes, evidence was insufficient because of too few studies. Moreover, results that were conclusive often suggested lack of clinical effect. Further research is needed and should address these evidence gaps with comparative studies that enroll enough patients to detect clinically meaningful improvements in important validated asthma outcomes.
